MEDICAL POLICY DETAILS

<table>
<thead>
<tr>
<th>Medical Policy Title</th>
<th>MAGNETIC RESONANCE IMAGING–PROSTATE/MULTIPARAMETRIC MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Number</td>
<td>6.01.46</td>
</tr>
<tr>
<td>Category</td>
<td>Technology Assessment</td>
</tr>
<tr>
<td>Effective Date</td>
<td>06/21/18</td>
</tr>
<tr>
<td>Revised Date</td>
<td>08/15/19</td>
</tr>
<tr>
<td>Product Disclaimer</td>
<td>• If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</td>
</tr>
<tr>
<td></td>
<td>• If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.</td>
</tr>
<tr>
<td></td>
<td>• If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</td>
</tr>
</tbody>
</table>

POLICY STATEMENT

I. Based upon our review and assessment of peer-reviewed literature including National Comprehensive Cancer Network (NCCN) clinical guidelines, MRI of the prostate is considered medically appropriate for initial workup or staging in men with one or more of the following high risk criteria:
   A. Any Gleason score with palpable disease outside of the prostate capsule (T3 or T4 disease); or
   B. PSA greater than 20 ng/ml; or
   C. Gleason score greater than or equal to 7; or
   D. Gleason score of 6 and:
      1. Tumor involving greater than 50% of one lobe (T2b); or
      2. Tumor involving both lobes (T2c); or
      3. PSA greater than 10ng/ml.

II. Based upon our review and assessment of peer-reviewed literature including National Comprehensive Cancer Network (NCCN) clinical guidelines MRI of the prostate is considered medically appropriate for diagnosis with at least one negative/non-diagnostic TRUS biopsy with documented plans for MRI guided biopsy or MRI/TRUS fusion biopsy and one of the following.
   A. Continued increase in PSA; or
   B. Abnormal DRE; or
   C. Focal Prostatic Intraepithelial Neoplasia (PIN) 1-2 lesions or atypical small acinar proliferation (ASAP).

III. Based upon our review and assessment of peer-reviewed literature including National Comprehensive Cancer Network (NCCN) clinical guidelines, MRI of the prostate is considered medically appropriate as part of an active surveillance program when there is suspected progression and one of the following:
   A. Changes in DRE; or
   B. Rising PSA with a negative TRUS biopsy; or
   C. TRUS biopsy which revealed progression of Gleason score; AND
   D. MRI is not used to determine if biopsy should be performed.

IV. Based upon our review and assessment of peer-reviewed literature including National Comprehensive Cancer Network (NCCN) clinical guidelines, an active surveillance program consists of the following medically appropriate protocol:
   A. PSA every 6 months; and
   B. Digital rectal exam every 12 months; and
   C. TRUS-guided prostate biopsy every 12 months; or
   D. mpMRI every 12 months.

Proprietary Information of Excellus Health Plan, Inc.
V. Based upon our review and assessment of peer-reviewed literature including National Comprehensive Cancer Network (NCCN) clinical guidelines MRI of the prostate is considered medically appropriate for restaging or recurrence in patients with one more of the following:
A. New finding on most recent CT or MRI that was inconclusive; or
B. PSA rising on 2 consecutive measurements while on endocrine/hormonal therapy; or
C. Clinical suspicion of recurrence or progression.

VI. Based upon our review and assessment of peer-reviewed literature including National Comprehensive Cancer Network (NCCN) clinical guidelines, MRI of the prostate is considered medically appropriate in patients with prior radical prostatectomy and any of the following:
A. Palpable anastomotic recurrence; or
B. PSA remains greater than 0.2 after at least 2 PSAs; or
C. Initial undetectable PSA increasing on 2 consecutive PSAs.

VII. Based upon our review and assessment of peer-reviewed literature including National Comprehensive Cancer Network (NCCN) clinical guidelines, MRI of the prostate is considered medically appropriate in patients with prior radiation therapy and any of the following:
A. Clinical suspicion of relapsed disease; or
B. PSA increasing on at least 2 consecutive values above post-XRT baseline.

VIII. Based upon our review and assessment of peer-reviewed literature including National Comprehensive Cancer Network (NCCN) clinical guidelines, MRI of the prostate is considered medically appropriate in all patients with one or more of the following:
A. Obvious progression by DRE with plans for prostatectomy or radiation therapy; or
B. Repeat TRUS biopsy for rising PSA shows progression to a higher Gleason score with plans for prostatectomy or radiation therapy.

POLICY GUIDELINES

I. When specific target lesion(s) is (are) detected on mpMRI prostate and classified as PIRADS 4 or 5, then 3D Rendering at independent workstation (CPT: 76377), for the radiologist to generate prostate segmentation data image set for target identification on MRI/TRUS fusion biopsy is appropriate. If there is no target lesion identified on MRI then 3D rendering and MRI/TRUS fusion biopsy is not generally indicated.

II. 3D rendering not requiring image postprocessing on an independent workstation (CPT: 76376) is inclusive to the MRI.

III. Several MRI-US fusion software-based targeted prostate biopsy platform specifications have been cleared for marketing by FDA through the 510(k) process. Fusion software include Artemis™ (Eigen, Grass Valley, CA), BioJet™ (D&K Technologies, Gurajat, India), BiopSee® (MedCom, Columbia, SC), Real-time Visual Sonography (Hitachi, Tokyo, Japan), UroNav™ (Invivo/Philips, Gainesville, FL), Urostation® (Koelis, Auburndale, MA), and Virtual Navigator (Esaote, Genoa, Italy).

IV. The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION

Prostate cancer is the most commonly diagnosed cancer and the third leading cause of cancer deaths among men in the United States. Prostate cancer is a complex, heterogeneous disease, ranging from microscopic tumors unlikely to be life-threatening to aggressive tumors that can metastasize, leading to morbidity or death. A major concern related to prostate cancer (PCA) screening and early detection is over diagnosis and overtreatment of indolent disease. Strategies to reduce over diagnosis are necessary, as are strategies to differentiate indolent from aggressive tumors. Better options are needed to stratify patients and to confirm the type of prostate cancer so that patients with aggressive disease receive treatment while those with a less aggressive disease may be treated more conservatively. Current methods to screen for prostate
cancer or to assess the risk of prostate cancer include PSA, digital rectal exam (DRE), and TRUS-guided prostate biopsy. These methods are limited by lack of specificity and ability to determine clinical significant prostate cancer.

Multi-parametric MRI (mpMRI) was developed to guide initial diagnosis of prostate cancer, pretreatment risk assessment and staging, guide and monitor active surveillance and to direct or target the prostate biopsy. mpMRI is composed of 3 imaging pulse sequences which combine to form both anatomic and functional images; T2 weighted imaging, diffusion weighted imaging (DWI), and dynamic contrast enhanced imaging (DCE), each with a specific function and result. If lesions are observed on mpMRI, they are assigned a PI-RADS score ranging from 1 to 5. The PI-RADS score indicate the likelihood of clinical significant prostate cancer with a score of 1 being the least suspicious to 5 having the highest suspicion for significant prostate cancer. Evidence suggests that mpMRI detects more aggressive disease and less indolent cancer. Used as the ‘gatekeeper’ or triage test, multi-parametric MRI can improve the patient pathway by reducing the number of TRUS biopsies. Likewise, men can avoid the potential for over-diagnosis and over-treatment of prostate cancer that can result when a biopsy is performed. MRI can be obtained using a 1.5T or 3.0T magnet and with or without the use of an endorectal coil.

RATIONALE

Faria et al., examined the cost effectiveness of MR Imaging compared with current treatment guidelines. Data for the model was obtained from the Prostate MR Imaging Study, the largest accuracy study on the use of mpMRI and transrectal ultrasound-guided biopsy in the diagnosis of prostate cancer. Results showed that the use of mpMRI first and then up to two MRI-targeted TRUS biopsies detects more clinically significant cancers per pound spent than a strategy using TRUS biopsy first (sensitivity = 0.95 [95% confidence interval {CI} 0.92–0.98] vs 0.91 [95% CI 0.86–0.94]) and is cost effective (ICER = £7,076 (£8350/QALY gained)). The evidence presented suggests that mpMRI is cost effective as the first test for the diagnosis of prostate cancer, when followed by an MRI-targeted TRUS biopsy in men in whom the mpMRI suggests a suspicion for clinically significant cancer.

The National Comprehensive Cancer Network Prostate Cancer (NCCN) (2019) guidelines state before starting on an active surveillance program, mpMRI and/or prostate biopsy should be considered to confirm candidacy for active surveillance. Men with PI-RADS 4 or 5 on mpMRI have an increased risk of biopsy progression during active surveillance. The current NCCN recommendations for the active surveillance program include PSA no more often than every 6 months, DRE no more often than every 12 months, repeat prostate biopsy no more often than every 12 months, and repeat mpMRI no more often than every 12 month unless clinically indicated. Early experience support the utilization of mpMRI in biopsy protocols to better risk-stratify men under active surveillance. However, more recent studies have shown that a significant proportion of high-grade cancers are detected with systematic biopsy and not targeted biopsy in men on active surveillance.

The AUA Policy Statement on the Use of Multiparametric MRI in the diagnosis, staging and management of prostate cancer recommendations include an investigational statement for mpMRI used alone for screening of prostate cancer for routine prostate screening. There is insufficient evidence to recommend mpMRI in every biopsy naïve patient considering biopsy. There is minimal evidence and a lack of a consensus statement for MRI and MRI targeted biopsy in men with previous negative biopsy but there is evidence to support mpMRI in men with increasing PSA following a negative biopsy. There is limited evidence of the diagnostic accuracy of mpMRI in follow-up of men after radical prostatectomy or focal therapies. There is a lack of evidence that mpMRI can be used as a primary test for surveillance, but MRI combined with a biopsy may improve outcomes as part of an active surveillance program. This area is evolving with a need for more data and studies.

The Ontario Cancer Care Prostate Cancer Diagnosis Pathway (2015) suggests multi-parametric MRI for men with previous negative prostate biopsy who have suspicious DRE or rising PSA or in men with a suspicious biopsy who are undergoing a subsequent biopsy.

The 2014 National Institute for Health and Care Excellence guidelines on the diagnosis and treatment of prostate cancer (CG175) recommends considering mpMRI (using T2- and diffusion-weighted imaging) for men with a negative TRUS 10- or 12-core biopsy to determine whether another biopsy is needed. Another biopsy should not be offered if the mpMRI is negative unless additional risk factors are present.
CODES

- Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.
- CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

CPT Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>76377</td>
<td>3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation</td>
</tr>
<tr>
<td>76942</td>
<td>Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation</td>
</tr>
<tr>
<td>77021</td>
<td>Magnetic resonance guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation</td>
</tr>
<tr>
<td>72195</td>
<td>Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)</td>
</tr>
<tr>
<td>72197</td>
<td>Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences</td>
</tr>
</tbody>
</table>

HCPCS Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No specific code(s)</td>
</tr>
</tbody>
</table>

ICD10 Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C61</td>
<td>Malignant neoplasm of prostate</td>
</tr>
<tr>
<td>D07.5</td>
<td>Carcinoma in situ of prostate</td>
</tr>
<tr>
<td>D29.1</td>
<td>Benign neoplasm of prostate</td>
</tr>
<tr>
<td>D40.0</td>
<td>Neoplasm of uncertain behavior of prostate</td>
</tr>
<tr>
<td>Z12.5</td>
<td>Encounter for screening for malignant neoplasm of prostate</td>
</tr>
<tr>
<td>Z85.46</td>
<td>Personal history of malignant neoplasm of prostate</td>
</tr>
</tbody>
</table>

REFERENCES


Glass AS and Dall’Era MA. Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. BJU Int 2019 Feb 11 [Epub ahead of print].


Johnson DC and Reiter RE. Multi-parametric magnetic resonance imaging as a management decision tool. Transl Androl Urol 2017 Jun;6(3):472-482.


*Key Article

**KEY WORDS**

Multiparametric MRI, MRI/US fusion biopsy, MRI targeted prostate biopsy, MRI pelvis

**CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

There is currently no National Coverage Determinations (NCD) or Local Coverage Determinations (LCD) for Magnetic Resonance Imaging of the prostate or Multiparametric MRI.